<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16625">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01895309</url>
  </required_header>
  <id_info>
    <org_study_id>SB4-G31-RA</org_study_id>
    <nct_id>NCT01895309</nct_id>
  </id_info>
  <brief_title>A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy</brief_title>
  <official_title>A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB4 Compared to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Bioepis Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Bioepis Co., Ltd.</source>
  <oversight_info>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, parallel group, multicentre clinical study to evaluate
      the efficacy, safety, pharmacokinetics and immunogenicity of SB4 compared to Enbrel in
      subjects with moderate to severe Rheumatoid Arthritis (RA) despite Methotrexate (MTX)
      therapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>American College of Rheumatology 20% response criteria (ACR20)</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACR20</measure>
    <time_frame>Week 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology 50% response criteria (ACR50)</measure>
    <time_frame>Week 24, Week 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity score based on a 28 joint count (DAS28)</measure>
    <time_frame>Week 24, Week 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">498</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>SB4 (proposed biosimilar to etanercept)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SB4 50 mg/week via subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enbrel (etanercept)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enbrel 50 mg/week via subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enbrel (etanercept)</intervention_name>
    <arm_group_label>Enbrel (etanercept)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB4 (proposed biosimilar to etanercept)</intervention_name>
    <arm_group_label>SB4 (proposed biosimilar to etanercept)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed as having RA according to the revised 1987 ACR criteria for at least 6
             months but not exceeding 15 years prior to Screening

          -  Have moderate to severe active disease despite MTX therapy defined as having more
             than or equal to six swollen joints and more than or equal to six tender joints and
             either erythrocyte sedimentation rate (ESR, Westergren) ≥ 28 mm/h or serum C-reactive
             protein ≥ 1.0 mg/dL

          -  Must have been treated with MTX for at least 6 months prior to Randomisation and on a
             stable dose of MTX 10-25 mg/week given at least 4 weeks prior to Screening

          -  Female subjects who are not pregnant or nursing at Screening and who are not planning
             to become pregnant from Screening until 2 months after the last dose of
             investigational product

        Exclusion Criteria:

          -  Have been treated previously with any biological agents including any tumour necrosis
             factor inhibitor

          -  Have a known hypersensitivity to human immunoglobulin proteins or other components of
             Enbrel or SB4

          -  Have a positive serological test for hepatitis B or hepatitis C or have a known
             history of infection with human immunodeficiency virus

          -  Have a current diagnosis of active tuberculosis

          -  Have had a serious infection or have been treated with intravenous antibiotics for an
             infection within 8 weeks or oral antibiotics within 2 weeks prior to Randomisation.

          -  Have any of the following conditions

               1. Other inflammatory or rheumatic diseases.

               2. History of any malignancy within the previous 5 years prior to Screening

               3. History of lymphoproliferative disease including lymphoma.

               4. History of congestive heart failure

               5. Physical incapacitation (ACR functional Class IV or wheelchair-/bed-bound).

               6. History of demyelinating disorders.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiri Vencovsky, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charles University, Czech Republic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 12, 2014</lastchanged_date>
  <firstreceived_date>July 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Etanercept</keyword>
  <keyword>Biosimilar</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>TNFR-Fc fusion protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
